Tactile Medical Launches Next-Generation AffloVest Airway Clearance Therapy
Globe Newswire (Tue, 2-Jun 8:00 AM ET)
Tactile Medical to Present at the William Blair 46th Annual Growth Stock Conference
Globe Newswire (Wed, 20-May 4:05 PM ET)
Tactile Systems Technology, Inc. Reports First Quarter 2026 Financial Results
Globe Newswire (Mon, 4-May 4:05 PM ET)
Tactile Medical to Release First Quarter of Fiscal Year 2026 Financial Results on May 4, 2026
Globe Newswire (Mon, 20-Apr 4:05 PM ET)
Market Chameleon (Wed, 18-Feb 5:31 AM ET)
TCMD Sees Revenue Climb 17% and Unveils $25M Share Repurchase: Financials Signal Renewed Growth
Market Chameleon (Tue, 4-Nov 5:31 AM ET)
TCMD Delivers 17% Revenue Growth, Boosts 2025 Outlook and Launches $25 Million Buyback
Market Chameleon (Tue, 4-Nov 2:05 AM ET)
Tactile Systems Technology Inc is a medical technology company. The company is engaged in developing and providing medical devices for the treatment of chronic diseases. The firm's proprietary platform flexitouch system, provides a home-based solution for lymphedema patients. The entire system is another home solution for patients with chronic swelling and actitouch system for chronic venous insufficiency patients that may be worn throughout the day.
Tactile Systems Technology trades on the NASDAQ stock market under the symbol TCMD.
As of July 10, 2026, TCMD stock price declined to $29.37 with 108,682 million shares trading.
TCMD has a beta of 0.37, meaning it tends to be less sensitive to market movements. TCMD has a correlation of 0.00 to the broad based SPY ETF.
TCMD has a market cap of $662.48 million. This is considered a Small Cap stock.
Last quarter Tactile Systems Technology reported $75 million in Revenue and -$.08 earnings per share. This beat revenue expectation by $5 million and missed earnings estimates by -$.04.
In the last 3 years, TCMD traded as high as $37.77 and as low as $8.61.
The top ETF exchange traded funds that TCMD belongs to (by Net Assets): IWM, VTI, VXF, IWO, AVUV.
TCMD has outperformed the market in the last year with a price return of +189.9% while the SPY ETF gained +21.9%. TCMD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.6% and +4.9%, respectively, while the SPY returned +11.0% and +2.6%, respectively.
TCMD support price is $29.77 and resistance is $31.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TCMD shares will trade within this expected range on the day.